RESICstance is futile-but not in glioblastoma.
Genomic alterations that occur early in tumorigenesis represent fundamental diver lesions and are perhaps of highest priority as a means to intervene therapeutically. In this issue of Cancer Cell, Ozawa and colleagues apply an algorithm to identify early events in glioblastoma and validate their findings in a rigorous manner.